Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Carlos Martinez joins Ethics Talk to discuss his article, coauthored with Drs Lauren Carruth, Hannah Janeway, Lahra Smith, Katharine M. Donato, Carlos Piñones-Rivera, James Quesada, and Seth Holmes: “How Should Clinicians Express Solidarity with Asylum Seekers at the US-Mexico Border?”
Dr José G. Pérez-Ramos joins Ethics Talk to discuss his article, coauthored with Drs Adriana Garriga-López and Carlos E. Rodríguez-Díaz: “How Is Colonialism a Sociostructural Determinant of Health in Puerto Rico?”
A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.
The picture that emerges from study of physician economic behavior is mixed, but from the intensity of responses by some professional societies to Medicare's coding modifier proposal, it appears that economic incentives matter a lot to many of their members.
Any use of nonanonymous student surveys will compromise the ability of schools to obtain valid data on mistreatment of students and attendant efforts to reduce the problem.